Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05829772
Other study ID # 2146-WT
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 20, 2021
Est. completion date April 2024

Study information

Verified date May 2023
Source Epicentre
Contact Anais Broban
Phone +33140215429
Email anais.broban@epicentre.msf.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This project aims to fill this essential knowledge gap by assessing the impact of oral cholera vaccine mass campaigns in 2 sites (urban and rural) in DRC, described in this protocol. The evidence generated from this project will be key to develop future strategies regarding cholera vaccine use in endemic settings, including places with higher burden in terms of cholera mortality


Description:

The project will comprise three different components: Clinical cholera surveillance to measure cholera diseases incidence in selected African hotspots targeted by vaccination. Serial serological surveys to measure the prevalence of recent cholera infection (within the last 12 months). Identification and follow up of individuals with positive V. cholerae shedding (symptomatic or asymptomatic) among sero-survey participants and among household members of cholera confirmed cases. The present protocol relates to the setup of seroprevalence surveys and the follow up of individuals with positive V. cholerae shedding identified through seroprevalence surveys, in DRC. This protocol will allow us to assess if a large vaccination campaign reaching high coverage in cholera hotspot in Africa can allow sustained control of cholera for at least two years, by fulfilling the following specific objectives: 1. To calculate the proportion of individuals infected with cholera recently (i.e. previous year or last 2 months) before the campaign distribution or in non-vaccinated zones (baseline survey, rural site) or following the mass OCV campaign and before the start of the usual cholera season (pre-season survey, urban site). 2. To assess proportion of individuals recently infected (i.e. infected in the last two months or in the last year) during the expected peak-week of cholera in the area (peak survey, urban site) and at the end of the expected cholera season (post-season survey), as compared to baseline or pre-season survey. 3. To assess the intra-household transmission and correlation in cholera recent infections among vaccinated and non-vaccinated households (post-season survey) 4. To compare mortality linked to diarrheal diseases and potential cholera in the community of rural site before and after vaccination 5. To assess the duration of shedding among vaccinated and unvaccinated individuals and the duration of viable V. cholerae in the peri-household environment. 6. To measure the secondary cholera attack rates (symptomatic and asymptomatic) at household level among vaccinated and unvaccinated individuals following the identification of an index case in a given household.


Recruitment information / eligibility

Status Recruiting
Enrollment 7000
Est. completion date April 2024
Est. primary completion date April 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - All persons, 1. Living in the randomly-selected households in targeted area AND 2. Randomly selected among household members. Inclusions will be limited to 1 participant per household, except for one survey AND 3. Giving his/her consent (or assent for children 13 to 17 years old) to participate in the study Exclusion Criteria: - People who decline to participate will be excluded from the study. For 2nd survey in Goma only: members of the household who cannot be reached after 2 attempts will be excluded.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Congo, The Democratic Republic of the Epicentre/Médecins Sans Frontières Bukama Haut-Lomami
Congo, The Democratic Republic of the Médecins Sans Frontières France Goma Nord Kivu

Sponsors (6)

Lead Sponsor Collaborator
Epicentre Institut National de Recherche Biomédicale. Goma, République Démocratique du Congo, Institut Pasteur, Medecins Sans Frontieres, France, Ministry of Public Health, Democratic Republic of the Congo, Wellcome Trust

Country where clinical trial is conducted

Congo, The Democratic Republic of the, 

Outcome

Type Measure Description Time frame Safety issue
Primary To better characterize cholera immunization in the population of cholera hotspot in Africa and assess the impact of a large vaccination campaign reaching high coverage Cholera-specific antibody levels will be measured in all participants for each surveys. Serial surveys will allow monitoring level of antibodies over time following the vaccination campaign 2 years
Secondary Calculate proportion of individuals infected with cholera (previous year or last 2 months) before the campaign distribution or in non-vaccinated zones or following the massOCV campaign and before the start of cholera season:pre-season survey, urban site. 2 years
Secondary Assess proportion of individuals infected (the last 2 months or previous year) during the expected peak-week of cholera in the area and at the end of the expected cholera season (post-season survey), as compared to baseline or pre-season survey. 2years
Secondary To assess the intra-household transmission and correlation in cholera recent infections among vaccinated and non-vaccinated households (post-season survey) 2 years
Secondary To compare mortality linked to diarrheal diseases and potential cholera in the community of rural site before and after vaccination 2 years
Secondary To assess the duration of shedding among vaccinated and unvaccinated individuals and the duration of viable V. cholerae in the peri-household environment. 2 years
Secondary To measure the secondary cholera attack rates (symptomatic and asymptomatic) at household level among vaccinated and unvaccinated individuals following the identification of an index case in a given household. 2 years
See also
  Status Clinical Trial Phase
Completed NCT01895855 - Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Phase 3
Completed NCT01339845 - Introduction of Cholera Vaccine in Bangladesh N/A
Completed NCT04760236 - Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shancholâ„¢ Phase 3
Recruiting NCT04326478 - Single Dose Azithromycin to Prevent Cholera in Children Phase 2
Recruiting NCT06104345 - Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines Phase 4
Completed NCT02928341 - Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo N/A
Completed NCT02864433 - Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts
Recruiting NCT06003816 - Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI) N/A
Not yet recruiting NCT05771779 - Co-administration Study of OCV, TCV and MR Phase 3
Not yet recruiting NCT06455852 - Correlates of Protection for Cholera N/A
Completed NCT04150250 - Cholera Anti-Secretory Treatment Trial Phase 2
Terminated NCT00624975 - Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants Phase 2
Completed NCT00226616 - Zinc Supplementation in Cholera Patients Phase 3
Completed NCT03373669 - Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine Phase 4
Completed NCT02094586 - A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults Phase 3
Completed NCT02100631 - A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults Phase 3
Completed NCT01823939 - PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera Phase 1
Completed NCT01365442 - Pilot Introduction of Oral Cholera Vaccine in Orissa, India N/A
Completed NCT00128011 - Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine Phase 2
Completed NCT00672308 - Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Phase 2